|
Oct 9
|
Bio-Thera and Richter Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, for EU countries, UK, Switzerland and other selected countries
|
|
Jul 25
|
Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda® (Pembrolizumab)
|
|
Jul 24
|
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, a Proposed Biosimilar to Stelara® in the US and EU
|
|
Dec 7
|
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
|
|
Nov 29
|
Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara®
|